Ulrike Lorch

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 12

Top Topics

Plasmodium Falciparum

Immune Response

Top Venues

British journal of clinical pharmacology

Clinical and translational science

European journal of drug metabolism and pharmacokinetics

This page only lists publications with an associated author ORCID identifier.

Publications

Andrea Kuemmerle, Denis Gossen, Annick Janin, Andrew Stokes, Nada Abla, Maja Szramowska, Ulrike Lorch, Myriam El Gaaloul, Isabelle Borghini Fuhrer, Stephan Chalon
Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin. Clinical and translational science 17 (4) (2024)
Ulrike Lorch, Charles Vincent
The safety of early phase clinical trials: Bridging the gap between governance and practice. British journal of clinical pharmacology 90 (7) (2024)
Andrea Kuemmerle, Denis Gossen, Annick Janin, Andrew Stokes, Nada Abla, Maja Szramowska, Ulrike Lorch, Myriam El Gaaloul, Isabelle Borghini Fuhrer, Stephan Chalon
Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin. Clinical and translational science 17 (4) (2024)
Andrea Kuemmerle, Denis Gossen, Annick Janin, Andrew Stokes, Nada Abla, Maja Szramowska, Ulrike Lorch, Myriam El Gaaloul, Isabelle Borghini Fuhrer, Stephan Chalon
Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin. Clinical and translational science 17 (4) (2024)
Andrea Kuemmerle, Denis Gossen, Annick Janin, Andrew Stokes, Nada Abla, Maja Szramowska, Ulrike Lorch, Myriam El Gaaloul, Isabelle Borghini Fuhrer, Stephan Chalon
Randomized, placebo-controlled, double-blind phase I trial of co-administered pyronaridine and piperaquine in healthy adults of sub-Saharan origin. Clinical and translational science 17 (4) (2024)
Ulrike Lorch, Charles Vincent
The safety of early phase clinical trials: Bridging the gap between governance and practice. British journal of clinical pharmacology (2024)
Jӧrg Täubel, Ulrike Lorch, Georg Ferber, Christopher S Spencer, Anne Freier, Simon Coates, Myriam El Gaaloul, Cristina Donini, Mohamed Farouk Chughlay, Stephan Chalon
Concentration-QT modelling of the novel DHFR inhibitor P218 in healthy male volunteers. British journal of clinical pharmacology (2021)
Mohamed Farouk Chughlay, Emilie Rossignol, Cristina Donini, Myriam El Gaaloul, Ulrike Lorch, Simon Coates, Grant Langdon, Tim Hammond, Jörg Möhrle, Stephan Chalon
First-in-human clinical trial to assess the safety, tolerability and pharmacokinetics of P218, a novel candidate for malaria chemoprotection. British journal of clinical pharmacology 86 (6) (2020)
Helen Dooner, Gill Mundin, Sabine Mersmann, Carla Bennett, Ulrike Lorch, Mercedes Encabo, Marisol Escriche, Gregorio Encina, Kevin Smith
Pharmacokinetics of Tramadol and Celecoxib in Japanese and Caucasian Subjects Following Administration of Co-Crystal of Tramadol-Celecoxib (CTC): A Randomised, Open-Label Study. European journal of drug metabolism and pharmacokinetics 44 (1) (2019)
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch
Coadministration of the prostaglandin F2α receptor antagonist preterm labour drug candidate OBE022 with magnesium sulfate, atosiban, nifedipine and betamethasone. British journal of clinical pharmacology 85 (7) (2019)
Valerie Cuvier, Ulrike Lorch, Stephan Witte, Aurelie Olivier, Sebastien Gibot, Isabelle Delor, Jean-Jacques Garaud, Marc Derive, Margarita Salcedo-Magguilli
A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition. British journal of clinical pharmacology 84 (10) (2018)
Oliver Pohl, Line Marchand, Jean-Pierre Gotteland, Simon Coates, Jörg Täubel, Ulrike Lorch
Pharmacokinetics, safety and tolerability of OBE022, a selective prostaglandin F2α receptor antagonist tocolytic: A first-in-human trial in healthy postmenopausal women. British journal of clinical pharmacology 84 (8) (2018)